From Genome Exploration to Drug Development

FDA's plan to establish pharmacogenomic policies spurs concerns among manufacturers, particularly in regard to how the policies will affect new-drug testing and approval.

Related Content:

Regulatory WatchPharmaceutical Technology-06-02-2003

Major Challenges Ahead for FDA and Pharma

FDA Grapples with the Promise and Perils of Gene Therapy

Pandemic Alters Policies and Practices for Drug Development and Regulation